Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs

Jan Krönke,1 Ralf Kittler,2 Frank Buchholz,2 Marc P. Windisch,1 Thomas Pietschmann,1 Ralf Bartenschlager,1,2* and Michael Frese1‡

Department of Molecular Virology, Hygiene Institute, University of Heidelberg, D-69120 Heidelberg,1 and Max-Planck-Institute for Molecular Cell Biology and Genetics, D-01307 Dresden,2 Germany

Received 8 October 2003/Accepted 4 December 2003

Persistent infection with hepatitis C virus (HCV) is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. It has recently been shown that HCV RNA replication is susceptible to small interfering RNAs (siRNAs), but the antiviral activity of siRNAs depends very much on their complementarity to the target sequence. Thus, the high degree of sequence diversity between different HCV genotypes and the rapid evolution of new quasispecies is a major problem in the development of siRNA-based gene therapies. For this study, we developed two alternative strategies to overcome these obstacles. In one approach, we used endoribonuclease-prepared siRNAs (esiRNAs) to simultaneously target multiple sites of the viral genome. We show that esiRNAs directed against various regions of the HCV coding sequence as well as the 5' nontranslated region (5' NTR) efficiently block the replication of subgenomic and genomic HCV replicons. In an alternative approach, we generated pseudotyped retroviruses encoding short hairpin RNAs (shRNAs). A total of 12 shRNAs, most of them targeting highly conserved sequence motifs within the 5' NTR or the early core coding region, were analyzed for their antiviral activities. After the transduction of Huh-7 cells containing a subgenomic HCV replicon, we found that all shRNAs targeting sequences in domain IV or nearby coding sequences blocked viral replication. In contrast, only one of seven shRNAs targeting sequences in domain II or III had a similar degree of antiviral activity, indicating that large sections of the NTRs are resistant to RNA interference. Moreover, we show that naive Huh-7 cells that stably expressed certain 5' NTR-specific shRNAs were largely resistant to a challenge with HCV replicons. These results demonstrate that the retroviral transduction of HCV-specific shRNAs provides a new possibility for antiviral intervention.

Hepatitis C virus (HCV) is an enveloped virus with a single-stranded 9.6-kb RNA genome of positive polarity (reviewed in reference 4). The 5' nontranslated region (NTR) of the genome contains an internal ribosome entry site (IRES) that directs the translation of a single long open reading frame. The encoded polyprotein is co- and posttranslationally cleaved into 10 viral proteins (core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). Recently, the production of an additional viral protein by a ribosomal frame shift has been reported (66, 69). HCV has been classified as a member of the genus Hepacivirus within the family Flaviviridae (62). Based on nucleotide sequence comparisons, HCV genomes can be grouped into at least six genotypes, or clades, that differ from each other by 31 to 34%. Furthermore, several subtypes have been defined, with a nucleotide sequence diversity of about 20%. In Western Europe and the United States, infections caused by genotypes 1a and 1b are the most frequent, followed by infections with genotype 2 and 3 viruses. The other genotypes are rare and can only be found in distinct geographical regions, such as Egypt (genotype 4), South Africa (genotype 5), and Southeast Asia (genotype 6). The genomic variability of HCV is due to the high error rate of the viral RNA-dependent RNA polymerase, which has been calculated to be in the range of about 10^{-3}-10^{-4} (42). This number is in line with the mutation rates of 1.44 \times 10^{-3} and 1.92 \times 10^{-3} base substitutions per site per year that were found in a chronically infected human and chimpanzee, respectively (47, 48).

HCV has infected an estimated 170 million people worldwide (68). In most cases, the virus has established a persistent infection, frequently associated with chronic hepatitis and liver fibrosis. Chronic hepatitis C often progresses to cirrhosis and eventually to hepatocellular carcinoma (26, 60). Currently, hepatitis C patients are treated with alpha interferon (IFN-α) alone or in combination with ribavirin. However, there is still no cure for a large proportion of patients, even with the most advanced therapy regimens (43). Thus, alternative therapeutic approaches for chronic hepatitis C are needed.

RNA interference (RNAi) is an ancient mechanism of sequence-specific gene regulation. RNAi pathways are known to regulate heterochromatin formation, protein translation, and RNA degradation (reviewed in reference 23). The latter is initiated by Dicer, a member of the RNase III family that chops double-stranded RNA (an intermediate in the replication of many, if not all, viruses) into so-called small interfering RNAs (siRNAs) that have a length of 21 to 25 nucleotides, 3' overhangs of 2 or 3 nucleotides, and phosphorylated 5' ends. Dicer is also known to process the precursor of a recently discovered species of noncoding RNAs, named micro-RNAs (miRNAs) or small temporal RNAs. These transcripts are about 60 to 80 nucleotides long and form stem-loop hairpins

* Corresponding author. Mailing address: Abteilung Molekulare Virologie, Hygiene Institut, Universität Heidelberg, Otto-Meyerhof-Zentrum, Im Neuenheimer Feld 350, D-69120 Heidelberg, Germany. Phone for Michael Frese: 49-6221-56-4834. Fax: 49-6221-56-4570. E-mail: michael_frese@med.uni-heidelberg.de. Phone for Ralf Bartenschlager: 49-6221-56-4569. Fax: 49-6221-56-4570. E-mail: ralf_bartenschlager@med.uni-heidelberg.de.
with asymmetric bulges within the stem. Dicer cuts within the stem, thereby producing double-stranded RNAs of approximately 21 nucleotides. Both siRNAs and mature miRNAs induce posttranscriptional gene silencing by binding to a multicomponent complex that has been termed the RNA-induced silencing complex (RISC) (20, 22). In the case of siRNAs, the incorporation results in RNA unwinding. The complex is then guided to specific substrates by Watson-Crick base pairing between the now single-stranded siRNA and complementary nucleotides of the target molecule. Hereupon, the target is cleaved within the recognition sequence, which in most cases initiates its rapid degradation (46). This kind of RNAi is highly sequence specific. Even a single mismatch between the siRNA and its target sequence can dramatically decrease the efficiency of RNA degradation. A similar mechanism of degradation has been proposed for RNAs that encounter an miRNA-loaded RISC complex if the miRNA shows complete complementarity to the target, whereas imprecise base pairing seems to induce translational arrest rather than degradation (reviewed in references 3 and 11).

In plants, RNAi serves as a potent antiviral defense mechanism which has provoked the evolution of counteracting strategies by many viruses (reviewed in reference 36). For example, the p19 protein of tomato bushy stunt virus and related tombusviruses binds siRNAs, thereby blocking systemic silencing in plants (57). Recently, it was shown that flock house virus, an insect pathogen, also encodes a protein that inhibits RNAi (35). Whether mammalian viruses encounter RNAi-based defense mechanisms is not clear. Although mammalian cells express Dicer homologs, they normally do not produce siRNAs from exogenous double-stranded RNAs (discussed in reference 9). Instead, they activate the IFN system, which leads to the enhanced expression of numerous genes, including those that encode proteins with strong antiviral activities (19, 52). Nevertheless, RNAi can be used to inhibit virus replication in mammalian cells. It has been demonstrated that the transfection of virus-specific siRNAs efficiently inhibits the multiplication of human immunodeficiency virus type 1 (HIV-1) and of several other viruses (reviewed in reference 9). Most recently, it was shown that HCV RNA replication is also sensitive to RNAi (29, 51, 67, 73; M. Y. Seo, S. Abrignani, M. Houghton, and J. H. Han, Letter, J. Virol. 77:5810–5812, 2003). However, the notoriously error-prone replication of RNA viruses is a problem for the development of siRNA-based gene therapies. Here we report the use of endonuclease-prepared siRNAs (esiRNAs) to simultaneously target multiple sites of the HCV genome for degradation, a strategy that should prevent the evolution of escape mutants. Furthermore, we show that HCV replication can be blocked by means of retrovirally transduced short hairpin RNAs (shRNAs) directed against the 5′ NTR or nearby coding sequences.

**MATERIALS AND METHODS**

**Cells.** The Huh-7 cell clones 9-13, 20-1, and 9B (containing the HCV 1b replicon I377/NS3-3′/H77/DR) were obtained from the National Institutes of Health, Bethesda, Md. (B. Choe, National Institutes of Health, Bethesda, Md.). Similarly, the ApaLI-AIII fragment of pJ6CF (24) containing the HCV genotype 1a strain H77 (kindly provided by J. Bukh, National Institute of Health, Bethesda, Md.) was excised with ApaLI and EcoRI restriction enzymes. The resulting fragment was treated with the Klenow enzyme and inserted between the HindIII and NcoI sites of pFK-EMCV (40) to generate pFK-I389/NS3-3′/H77/wt. The H9004 regions of pCV-H77 (containing the NS3 to NS5B coding region) was amplified by using the primers S2066 (GCTGGCCCGCTCCTCAAAG), A-2284R (GGCGACAGCTGGTTGAGGAG), S-2284R (CTTCCGGATCAAGCACTGGC), and A-7555 (GCGGCCCACATCTAGCCCGG). Sequences were confirmed by direct sequencing. Note that given amino acid positions refer to the Con1 consensus genome. The replication construct I389/NS3-3′/Luc-1/Luc-2 (used in transient transfection experiments) was described previously under the name of Luc-ET (18, 41).

**Generation and transfection of HCV RNAs.** The generation of HCV RNAs by in vitro transcription and the electroporation of Huh-7 cells with these RNAs have been described previously (39, 41).

**Generation and transfection of esiRNAs.** PCR standard protocols and primers with 5′-terminal T7 or T3 promoter sequences were used to amplify fragments of the HCV genotypes 1a (strain H77), 1b (strain Con1), and 2a (strain HC-J6-CH, clone pJ6CF; kindly provided by J. Bukh). In addition, fragments of genes encoding firefly luciferase (Fluc), enhanced green fluorescent protein (EGFP), and β-galactosidase (LacZ) were amplified (for more detailed information, see Table 1 and Fig. 1A). PCR products were transcribed in vitro with a MEGAscript kit (Ambion, Austin, Tex.). Complementary transcripts were annealed, and the resulting double-stranded RNAs were digested with highly purified, recombinant RNase III essentially as described previously (8, 72). Cleavage products were purified by using QiAquick columns (Qiagen, Hilden, Germany), and the flowthrough was collected, and a heterogenous population of double-stranded RNA was obtained. Approximately 15 to 50 μg of the double-stranded RNA pellet was washed with 70% ethanol, purified esiRNAs were dissolved in double-distilled water, and the concentration was determined photometrically.

For the transfection of esiRNAs, cells were seeded into 6-well plates (10⁴ cells per well). About 48 h later, cells were transfected with esiRNAs or control RNAs [yeast tRNA or poly(C)] by the use of OptiMEM (Life Technologies) and the Oligofectamine transfection reagent (Invitrogen) according to the manufacturer’s recommendations.

**Construction of retroviral vectors encoding shRNAs.** The vector pBABE/H1/ SV40/EGFZ-DU3 was constructed by modifying the Moloney murine leukemia virus (Mo-MuLV)-based vector pBABE/puro (44). The puromycin coding sequence of pBABE/puro was replaced by a fragment of pZeo5-EGFZ containing an EGFP-zeocin fusion protein coding sequence (5) kindly provided by D. Lindemann, Institute of Virology, TU Dresden, Germany. The resulting construct was digested with XbaI and NotI and ligated to delete a large portion of the U3 region within the U2′ long terminal repeat (LTR). Next, a BglII restriction site was inserted into the EGFZ-zeocin coding sequence was destroyed by insertion of the nonpermissive construct with the Klenow enzyme and inserted between the EGFZ and BamHI restriction sites of the intermediate vector pBABE/SV40/E3GZ-DU3, thereby generating pBABE/H1/SV40/EGFZ-DU3 (Fig. 1B).
sequencing. Note that the sequences of all HCV-specific shRNAs can be deduced from their names, which refer to corresponding nucleotide positions of the Con1 genome (41). As an example of an HCV-specific shRNA, the secondary structure of HCV-321 is shown in Fig. 1C. The p53-specific shRNA, as used in our experiments, has been described previously (6), and the ORF3b shRNA, as described previously (58). Brieﬂy, 293T cells (14) were cotransfected with wild-type GFP (Molecular Probes, Eugene, Oreg.), respectively. Cells grown on glass coverslips were immunostained with the cyanine dye Cy3 (Dianova, Hamburg, Germany) as secondary antibody and 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Molecular Probes).

Luciferase assays and HCV RNA quantiﬁcation. The luciferase activity and the HCV RNA concentration were measured essentially as described previously (58). Briefly, 293T cells (14) were cotransfected with the parental vector pBABE-H1/SV40/EGZ (∆U3) (or constructs that encode shRNAs), pHIT60 (encoding the Gag-Pol proteins of Mo-MuLV) (58), and pc-σ2b-NS5b of S. aureus) (16) by the calcium phosphate precipitation method. The next day, cells were treated with 10 mM sodium butyrate for 9 h. After an additional incubation period of 16 h in the absence of sodium butyrate, supernatants were collected and the cell debris was removed by ﬁltration (pore size, 0.45 µm). The stock virus was either used directly after ﬁltration or stored at 4°C. The luciferase activity was detected by using either tools of the Hepatitis C Virus Database (http://hepatitis.ibcp.fr) or the VECTOR NTI ADVANCE program (INFORMAX, Bethesda, Md.). HCV sequences with the following database accession numbers were used: AJ238799 (strain Con1), AF009606 (strain H77), AF177036 (strain HC-J6b), D17763 (strain NZ1), D45193 (strain HEMAS1), Y13184 (strain EUH1480), and D84262 (strain Th580).

RESULTS

Inhibition of HCV replicons by esiRNAs. A sensitive and precise quantiﬁcation of HCV RNA replication can be achieved by using replicons encoding ﬂuorescent luciferase as a reporter (33). In an initial set of experiments, we transfected cells of the HuH-7 cell clone 9B that contained the subgenomic HCV genotype 1b replicon I389/NS3-3′/LucubiNeo-ET with HCV-speciﬁc esiRNAs and various control RNAs (for a schematic representation of the replicon and the positions of targeted sequences, see Fig. 1A). As shown in Fig. 2A, transfection of the ORF3 esiRNA preparation inhibited luciferase reporter gene expression in a dose-dependent manner. The effect was detectable as early as 24 h after transfection and became even more pronounced at later time points. We calculated that the transfection of 1.5 µg of esiRNAs per 2 × 10^5 cells suppressed the luciferase activity within 72 h to approximately 1% of the levels in untreated control cells. Interestingly, we observed that the transfection of unrelated control esiRNAs targeting coding sequences of EGFP or LacZ also reduced the luciferase activity, albeit to a much lesser extent (for unknown reasons, this phenomenon was observed only in some experiments). However, incubation with the transfection reagent alone or with mixtures of the transfection reagent and longer double-stranded RNAs such as poly(IC) had no effect on reporter gene expression. In additional experiments, we compared the antiviral activity of different HCV-speciﬁc esiRNAs. The results shown in Fig. 2B demonstrate that the luciferase reporter activity in 9B cells is inhibited to almost the same extent and with similar kinetics by esiRNAs targeting HCV coding sequences and by the highly structured 5′ NTR.

<table>
<thead>
<tr>
<th>Template (reference or source)</th>
<th>Primer name</th>
<th>Primer sequence (5′ → 3′)</th>
<th>Amplicon name</th>
<th>Amplicon size (nt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pFK-I389/NS3-3′/wt (40)</td>
<td>T7-5′NTR/1b_F</td>
<td>ATTAATACGACTCACTATAGGGGCAGCAGCACTCCACCACATAGAT</td>
<td>5′NTR/1b</td>
<td>337</td>
</tr>
<tr>
<td>pCV-H77C (70)</td>
<td>T7-ORF-1/1a_F</td>
<td>TTAATACGACTCACTATAGGGTCCTTGCTTTCTGAGGTC</td>
<td>ORF1/1a</td>
<td>999</td>
</tr>
<tr>
<td>pJ6CF-pGEM (71)</td>
<td>T7-ORF-2/1a_F</td>
<td>TTAATACGACTCACTATAGGGTCCTTGCTTTCTGAGGTC</td>
<td>ORF2/1a</td>
<td>1,125</td>
</tr>
<tr>
<td>pEGFPLuc (Clontech)</td>
<td>T7-Fluc_F</td>
<td>ATTAATACGACTCACTATAGGGTCCTTGCTTTCTGAGGTC</td>
<td>Fluc</td>
<td>737</td>
</tr>
<tr>
<td>pSV-paX (7)</td>
<td>T7-LacZ_F</td>
<td>ATTAATACGACTCACTATAGGGTCCTTGCTTTCTGAGGTC</td>
<td>LacZ</td>
<td>1,363</td>
</tr>
</tbody>
</table>

Downloaded from http://jvi.asm.org/ on September 22, 2017 by guest
Similar results were obtained for esiRNAs targeting the firefly luciferase coding sequence (data not shown). Next, we analyzed whether the complexity of our esiRNA preparations was a limiting factor in the inhibition of HCV RNA replication. To that end, we transfected 9B cells with a mixture of different esiRNAs (ORF1, ORF2, and ORF3) and compared the antiviral effect with that of the individual preparations. However, no enhanced antiviral activity was observed with mixed preparations (data not shown), indicating that the individual preparations contained enough different esiRNAs to cover a redundant number of target sites.

Previous time course experiments indicated that esiRNA-induced silencing is maximal after 6 days and levels off thereafter (72). To study whether HCV RNAs can be purged from transfected cells by the use of esiRNAs, we transfected 9B cells with HCV-specific or unrelated control esiRNAs and monitored the fates of the replicons by measuring the luciferase reporter gene activity up to 11 days posttransfection. Similar to the experiments described above, HCV-specific esiRNAs rapidly suppressed reporter gene expression by approximately 98% (compare Fig. 3A and 4A). Moreover, reporter gene expression did not recover in these cells (even 11 days after the transfection of HCV-specific esiRNAs). In contrast, the inhibition of reporter gene expression induced by nonrelated EGFP-specific esiRNAs was only transient, and at 7 days posttransfection, luciferase activities were comparable to those measured for untreated control cells (Fig. 3A). Based on experiments in which the expression of a host gene was silenced, we estimated that the efficiency by which we transfected esiRNAs into Huh-7 cells was in the range of 90 to 99% (data not shown). Thus, we inferred that consecutive transfections of HCV-specific esiRNA transfections might completely remove HCV replicons from 9B cells. The results shown in Fig. 3B demonstrate that this is indeed the case. Three days after the last of three consecutive transfections of HCV-specific esiRNAs, luciferase activities were close to the detection limit. We calculated the suppression compared to untreated control cells to be >99.97 and >99.98% for ORF1 and ORF3.
esiRNAs, respectively. In contrast, additional transfections of EGFP-specific esiRNAs did not further reduce luciferase expression levels. To confirm these findings, we determined the replicon copy number by quantitative RT-PCR. As shown in Fig. 3C, the reduction in reporter gene activity was always paralleled by an equivalent reduction in the number of replicon RNAs.

All experiments described so far were performed with cells containing a subgenomic replicon that does not encode the viral proteins core, E1, E2, p7, and NS2. Consequently, we...
could not rule out that one or more of these proteins interfere with RNAi. Therefore, we transfected cells of the Huh-7 cell clone 20-1 that contained the selectable genomic HCV replicon I389/Core-3'/5.1 with ORF1 or ORF3 esiRNAs. Since this replicon does not carry a reporter gene, we used quantitative RT-PCR and indirect immunofluorescence to measure viral protein expression. Thus, HCV structural proteins and the NS2 protease do not counteract the effect of esiRNAs. To substantiate this conclusion, we quantified the antiviral effect of esiRNAs in additional cell clones containing various HCV replicons (cell clones 9-13, 5-15, and 21-5 containing the replicons I377/NS3-3', I389/NS3-3', and I399/Core-3'/5.1, respectively). The results of these experiments confirmed that subgenomic replicons are not more susceptible to esiRNAs than genomic replicons (data not shown).

HCV genomes differ as much as 34% in their nucleotide sequences. Nevertheless, several genomic regions are highly conserved among all known HCV isolates (most notably, both NTRs, but also certain sequences within the core and NS5B coding regions). We speculated that these regions might well serve as potential binding sites for esiRNAs, which would allow the silencing of multiple genotypes with a single esiRNA preparation. To test this hypothesis, we transfected genotype 1a-, 1b-, or 2a-derived esiRNAs into 9B cells (containing the genotype 1b replicon I389/NS3-3'/LucUbNeo-ET) and measured the luciferase reporter activity. As shown in Fig. 5A, we found that only genotype 1b-derived esiRNAs efficiently inhibited reporter gene expression. To corroborate this finding, we assayed the antiviral activities of different esiRNA preparations in cells with the chimeric replicon I399/NS3-3'/DR, which contains the NS3 to NS5B coding sequence of a genotype 1a virus and the NTRs of a genotype 1b virus. In this experimental setting, we found that genotype 1a- but not genotype 1b-derived esiRNAs efficiently blocked HCV replication (Fig. 5B). However, slightly lower HCV RNA levels were detected in cells that had been transfected with heterologous ORF3 esiRNAs. Thus, it is tempting to speculate that individual esiRNA molecules that target the highly conserved sequence motifs within the NS5B sequence account for this phenomenon. In summary, these data suggest that the efficient silencing of multiple HCV genotypes is only possible with esiRNAs that target highly conserved regions of the viral genome.

**Inhibition of HCV replicons by shRNAs.** In an attempt to establish an alternative method to purge HCV RNAs from infected cells and to confer resistance against HCV infections, we explored the utility of shRNAs. These siRNA-like transcripts were first described by Brummelkamp and coworkers, who also demonstrated that the constitutive expression of shRNAs results in persistent silencing (6). These findings prompted us to design shRNAs to target highly conserved regions of the HCV genome. Since it is difficult to predict which sequence is targeted most efficiently, we tested a series of 12 HCV-specific shRNAs for the ability to inhibit HCV RNA replication. Eleven of these targeted various highly conserved sequence motifs within the 5' NTR or the core coding region, and one was directed against a comparatively variable sequence within the NS4B coding region (Fig. 6 and 7). For the delivery and constitutive expression of shRNAs, we constructed a retroviral vector that we named pBABE/H1/SV40/EGZ/ΔU3 (for details, see Materials and Methods). The main characteristic features of this Mo-MuLV-based vector construct are (i) a large deletion within the U3 region of the 3' LTR, (ii) a BglII/XhoI cloning site for the insertion of shRNA-encoding oligonucleotides downstream of an RNA polymerase III H1-RNA promoter, and (iii) an EGFP-zeocin cassette downstream of a simian virus 40 (SV40) promoter element.
vector to induce RNAi by using a human p53-specific shRNA (Fig. 1B). In a pilot experiment, we tested the ability of this representation of the secondary structure of the HCV 5’ NTR to induce RNAi in naive Huh-7 cells with a recombinant retrovirus that was designed previously (6). As expected, the retroviral vector (data not shown). Next, we infected 9B cells with different retroviruses that transduce HCV-specific or unrelated shRNAs and cultivated the cells for nearly 2 weeks in the presence of zeocin in order to select for transduced cells. The cells were then challenged with the cell culture-adapted subgenomic HCV replicon 1389/NS3-3’/Luc-ET (18, 41), and viral replication was quantified by measuring luciferase reporter activities. We found that those shRNAs which inhibited HCV replication in 9B cells also blocked HCV replication in this experiment (Fig. 8B). This result suggests that the transduction of shRNAs may indeed protect cells from HCV infections.

Taken together, the results demonstrate that the 5’ NTR of the HCV genome contains sequences that are highly susceptible to esiRNAs and shRNAs. Note that some of these sequences are extremely conserved, which might allow the inhibition of all known genotypes by universal shRNAs such as HCV-321. Furthermore, the results suggest that it may be possible in the near future to confer resistance against HCV infections by the constitutive expression of shRNAs.

**DISCUSSION**

In contrast to plants and invertebrates, mammals have not yet been reported to use RNAi as an antiviral defense mechanism. Nevertheless, RNAi can be initiated in mammalian cells artificially by the delivery of siRNAs (15). This technique has recently been used in cultured cells to block the replication of important human pathogens, such as HIV (10, 13, 27, 34, 45, 49) and HCV (29, 51, 67, 73; Seo et al., letter). In all of these studies, RNAi was induced in a highly specific manner by the use of chemically synthesized oligonucleotides, with the exception of the work of Yokota and coworkers, for which eukaryotic expression vectors to deliver HCV-specific siRNAs and shRNAs were also used (73). A problem with siRNAs as well as shRNAs, however, is that the efficiency with which they trigger RNAi varies dramatically and is difficult to predict (16, 24a). Another problem is the specificity with which they bind to their target sequences. Even a single nucleotide mismatch can completely abolish their capacity to induce RNAi (2, 12, 21). Given these limitations, it is challenging to design siRNAs that efficiently target all quasispecies of a given virus population. RNA viruses and retroviruses will be especially difficult to eradicate because of their notoriously error-prone mode of replication which allows the rapid evolution of escape mutants. Since esiRNAs are directed against multiple sites of a targeted sequence, they can be used to inhibit the replication of a heterogeneous population of related viruses. Furthermore, it seems extremely unlikely that a viral genome can accumulate enough point mutations to escape the antiviral activity of esiRNAs. Our results demonstrate that esiRNAs can indeed be used efficiently to block viral replication. Since esiRNAs are much...
cheaper to produce than chemically synthesized oligonucleotides, they represent a powerful and rather inexpensive molecular tool for many virologists.

Many plant viruses and an insect virus are known to encode proteins that counteract RNAi (35, 36). Interestingly, it was recently noted that the double-stranded RNA-binding protein of the mammalian orthoreovirus also inhibits RNAi if it is expressed as a recombinant protein in transgenic plants (37). Since the HCV core proteins bind RNA in a rather promiscuous manner (17, 53, 56), it is conceivable that the core protein also binds to esiRNAs, which would interfere with RNAi. However, our finding that the replication of subgenomic replicons is as sensitive as that of full-length HCV RNAs to the transfection of esiRNAs indicates that the core protein cannot counteract RNAi. This observation is in line with a recent study showing that the replication of a full-length HCV RNA is sensitive to RNAi induced by chemically synthesized siRNAs (51). Nevertheless, the data do not exclude the possibility that

FIG. 7. Target sequences of HCV-specific shRNAs. The CLUSTAL W algorithm (61) was used to align the first 389 nucleotides of the HCV Con1 consensus genome (genotype 1b) with homologous sequences of six other genomes representing genotypes 1a (strain H77), 2a (strain HC-J6CH), 3a (strain NZL1), 4a (strain HEMA51), 5a (strain EUH1480), and 6b (strain Th580). Black lines indicate sequences targeted by shRNAs. Coding nucleotides are highlighted in gray.
The core protein protects the viral genome from Dicer, which would block the endogenous production of siRNAs. It is, however, unlikely that such an ability of core is of relevance to the replication of HCV in human cells, as most mammals do not seem to use RNAi as an antiviral defense mechanism.

The 5' NTR has long been a focus of antiviral research because this highly conserved region of the HCV genome is indispensable for both RNA translation and replication. In a number of studies, antisense oligodeoxynucleotides have been tested for the ability to block the activity of the HCV IRES (1, 63, 65). Furthermore, the 5' NTR has been targeted by ribozymes containing complementary sequences (38). These studies indicated that sequences in close proximity to the start codon are most suitable for the efficient inhibition of HCV RNA translation in a number of surrogate assays. These observations were confirmed by our finding that all domain IV-specific shRNAs (HCV-321 and HCV-334) blocked the replication of HCV RNAs. In contrast, none of the domain II-specific shRNAs and only one of five domain III-specific shRNAs (HCV-138) showed a similar degree of antiviral activity. We do not know why most of the shRNAs that targeted domain II and III failed to induce RNAi. However, one could speculate that some of them target RNA sequences that are not accessible to the RISC because of unfavorable secondary structures (for a definition of target requirements, see reference 32). Furthermore, it is possible that the tight interaction of the HCV IRES with components of the cellular translation machinery protects large sections of the 5' NTR from binding shRNAs. In this context, it is interesting that most of domain III is involved in the recruitment of the 40S ribosomal subunit and the subsequent binding of the eukaryotic initiation factor eIF3 (reviewed in reference 54). Furthermore, it was shown by Spahn and coworkers that domain II is heavily engaged in the induction and/or stabilization of extensive conformational changes that take place in the 40S subunit before the 60S subunit joins the complex (59). Moreover, several noncanonical translation factors and other yet uncharacterized cellular proteins have been identified which bind to the HCV IRES (reviewed in reference 4) and may thereby also interfere with the binding of shRNAs.

Recently, Yokota and coworkers tested five different 5' NTR-specific chemically synthesized siRNAs for the ability to block the replication of a subgenomic HCV replicon (73). The findings of Yokota and coworkers are somewhat difficult to compare with ours because the target sequences of their siRNAs and those of our shRNAs do not match. Nevertheless, a few conclusions can be drawn. First, as with our shRNAs, the most effective siRNA targeted a sequence within domain IV which encompasses the start codon. Second, an siRNA that targeted the subdomain IIIe only slightly inhibited HCV replication (similar to shRNA HCV-279). Most interesting, however, is the observation that an siRNA that targeted domain II efficiently inhibited HCV RNA replication but failed to induce the degradation of mRNAs containing the HCV IRES. Notably, the 5' ends of that siRNA possess a pronounced sequence asymmetry (the strand that is complementary to the negative strand starts with a UAAC sequence, whereas the 5' sequence of the other strand is GCGU). Given the recent finding that the siRNA strand whose 5' end is less tightly paired to its complement is preferentially incorporated into the RISC (30, 55), it seems likely that this particular siRNA targets the 3' terminus of the HCV negative strand rather than the 5' NTR of the viral genome. It is tempting to speculate that some of our HCV-specific shRNAs also targeted the HCV negative strand, a mode of action which might have contributed to the antiviral activity of HCV-138.

A main goal of this study was the identification of shRNAs that can be used to target all common HCV genotypes. With
HCV-138 and HCV-321, we found two shRNAs that fulfill this criterion. Furthermore, we established a system that allows the efficient transduction of these shRNAs into potential host cells. This know-how may be used in future approaches to inhibit HCV replication in vivo.

ACKNOWLEDGMENTS

We are grateful to Reuven Agami, Jens Bukh, and Dirk Lindemann for the kind provision of reagents. Furthermore, we thank Nicole Krieger, Artur Kaul, Ulf Zeuge, and Ulrike Herian for technical assistance and Kerry Mills for critical reading of the manuscript. This work was supported by grants from the Bundesministerium für Bildung und Forschung (Kompetenzzentren Hepatitis, projects 01KI0102 and D10022130) and an Unrestricted Biomedical Research Grant in Infectious Diseases from the Bristol-Myers Squibb Foundation.

REFERENCES


